← Back to Search

Angiogenesis Inhibitor

DSP-7888 Dosing Emulsion for Glioblastoma

Phase 3
Waitlist Available
Research Sponsored by Sumitomo Pharma America, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥18.
KPS score of ≥60.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks after the patient has been off study treatment, every 3 months thereafter until death, the study closes, up to 24 months.
Awards & highlights

Study Summary

This trial is testing a new cancer treatment against the current best treatment for people with a certain type of brain tumor.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have a KPS score of ≥60.
Select...
You have recovered from the effect of all prior therapy to Grade 2 or less.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks after the patient has been off study treatment, every 3 months thereafter until death, the study closes, up to 24 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks after the patient has been off study treatment, every 3 months thereafter until death, the study closes, up to 24 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants Who Experienced a Dose-limiting Toxicity
Overall Survival (OS) of Patients With Recurrent or Progressive Glioblastoma Multiforme (GBM) Treated With DSP-7888 Dosing Emulsion Plus Bevacizumab (BEV) Versus BEV Alone
Secondary outcome measures
Duration of Response in Patients With Recurrent or Progressive GBM Treated With DSP-7888 Dosing Emulsion Plus Bevacizumab (BEV) Versus BEV Alone
Number of Participants With Adverse Events and Serious Adverse Events
Overall Survival (OS) of Patients With Recurrent or Progressive Glioblastoma Multiforme (GBM) Treated With DSP-7888 Dosing Emulsion Plus Bevacizumab (BEV) Versus BEV Alone at 12 Months
+3 more

Side effects data

From 2021 Phase 3 trial • 221 Patients • NCT03149003
27%
Hypertension
26%
Headache
19%
Fatigue
17%
Nausea
12%
Aphasia
12%
Constipation
12%
Diarrhoea
11%
Fall
11%
Seizure
10%
Proteinuria
10%
Alanine aminotransferase increased
10%
Insomnia
10%
Muscular weakness
9%
Hemiparesis
9%
Gait disturbance
8%
Dizziness
8%
Dysphonia
8%
Anxiety
8%
Pyrexia
8%
Arthralgia
7%
Aspartate aminotransferase increased
7%
Hyperglycaemia
7%
Hypokalaemia
7%
Vomiting
7%
Confusional state
7%
Urinary tract infection
6%
Asthenia
6%
Epistaxis
6%
Weight increased
6%
Decreased appetite
6%
Oedema peripheral
4%
Depression
4%
Memory impairment
3%
Weight decreased
3%
Upper respiratory tract infection
3%
Back Pain
2%
Dysphagia
2%
Cerebrovascular accident
2%
Cough
2%
Abdominal pain
2%
Pain in extremity
2%
Lymphocyte count decreased
1%
Thrombocytopenia
1%
Psychotic disorder
1%
Myalgia
1%
Hyponatraemia
1%
Hypertensive encephalopathy
1%
Hypomagnesaemia
1%
Urinary incontinence
1%
Encephalopathy
1%
Cerebral haemorrhage
1%
Hypertensive crisis
1%
Haematochezia
1%
Mental status changes
100%
80%
60%
40%
20%
0%
Study treatment Arm
Part 2 - Arm 2: Bevacizumab
Part 1 - Arm 1: DSP-7888 Dosing Emulsion Plus Bevacizumab
Part 2 - Arm 1: DSP-7888 Dosing Emulsion Plus Bevacizumab

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm 1: DSP-7888 Dosing Emulsion plus BevacizumabExperimental Treatment2 Interventions
Group II: Arm 2: BevacizumabActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DSP-7888 Dosing Emulsion
2017
Completed Phase 3
~300
Bevacizumab
2013
Completed Phase 4
~5280

Find a Location

Who is running the clinical trial?

Sumitomo Pharma America, Inc.Lead Sponsor
236 Previous Clinical Trials
52,571 Total Patients Enrolled
3 Trials studying Glioblastoma
128 Patients Enrolled for Glioblastoma
Sumitomo Dainippon Pharma Oncology, IncLead Sponsor
41 Previous Clinical Trials
6,438 Total Patients Enrolled
3 Trials studying Glioblastoma
128 Patients Enrolled for Glioblastoma
Sumitomo Pharma Oncology, Inc.Lead Sponsor
44 Previous Clinical Trials
6,759 Total Patients Enrolled
3 Trials studying Glioblastoma
128 Patients Enrolled for Glioblastoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there other places in town where this trial is taking place?

"This study is enrolling patients at 40 sites across North America. If you choose to participate in the trial, it is important to select a site that is geographically close to reduce travel burden."

Answered by AI

How many people are participating in this clinical trial at most?

"As of right now, this clinical trial is not looking for new patients. This study was first posted on December 8th, 2017 and updated as recently as April 4th, 2022. There are 458 other trials concerning glioblastoma currently enrolling participants and 376 studies involving DSP-7888 Dosing Emulsion that are actively recruiting patients."

Answered by AI

Could you explain the general purpose of DSP-7888 Dosing Emulsion?

"DSP-7888 Dosing Emulsion is most commonly used as an intervention for malignant neoplasms. It can also be prescribed to treat various conditions including recurrent platinum sensitive primary peritoneal cancer, stage iv epithelial ovarian cancer following initial surgical resection, locally advanced nonsquamous non-small cell lung cancer."

Answered by AI

What is the maximum recommended dosage for DSP-7888 Dosing Emulsion?

"There is some evidence of efficacy and multiple rounds of safety data, so our team at Power gives DSP-7888 a score of 3."

Answered by AI

Are there similar trials to DSP-7888 Dosing Emulsion?

"Currently, there are 376 active clinical trials looking into DSP-7888 Dosing Emulsion. Out of these, 99 have progressed to Phase 3 testing. The majority of research is taking place in Taibei, Taiwan; however, there are a total of 18909 locations running studies related to DSP-7888 Dosing Emulsion."

Answered by AI

Are there any open slots for new participants in this clinical trial?

"Unfortunately, this particular trial is not currently enrolling patients. Although, there are 458 trials for glioblastoma and 376 DSP-7888 Dosing Emulsion studies that are still seeking participants."

Answered by AI

Who else is applying?

What state do they live in?
California
What portion of applicants met pre-screening criteria?
Met criteria
~30 spots leftby Mar 2025